Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy

Biological Research

Volumn 47, Issue 1, 2014, Pages

  Rosas, Carlos ^a   Sinning, Mariana ^b   Ferreira, Arturo ^a   Fuenzalida, Marcela ^a   Lemus, David ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

Angiogenesis; Celecoxib; Tumor

Indexed keywords

ANGIOGENESIS INHIBITOR; CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE; VASCULOTROPIN A;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CHICK EMBRYO; CHICKEN; CHORIOALLANTOIS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; LUNG TUMOR; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; NICK END LABELING; PATHOLOGY; SECONDARY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; CHICKENS; CHORIOALLANTOIC MEMBRANE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; IN SITU NICK-END LABELING; LUNG NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PYRAZOLES; SULFONAMIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84916230960     PISSN: 07169760     EISSN: 07176287     Source Type: Journal    
DOI: 10.1186/0717-6287-47-27     Document Type: Article

References (44)

1. Bakhle YS: COX-2 and cancer: a new approach to an old problem. Br J Pharmacol 2001, 134:1137-1150
2. Cianchi F, Cortesini C, Bechi P, Fantappiè O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R, Masini E: Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001, 121:1339-1347
3. Dempke W, Rie C, Grothey A, Schmoll H: Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001, 127:411-417
4. Ragel B, Jensen R, Gillespie D, Prescott S, Couldwell W: Celecoxib inhibits meningioma tumor growth in a mouse xenograft model. Cancer 2007, 109(3):588-597
5. Xu X, Xie C, Wang X, Liu J, Yu Y, Hu H, Guo C: Selective inhibition of cycloooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo. Tohoku J Exp Med 2008, 215:149-157
6. Chun K, Surh Y: Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 2004, 68:1089-1100
7. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007, 6(4):273-286
8. Tosetti F, Ferrari N, De Flora S, Albini A: Angioprevention: angiogénesis is a common key target for cancer chemopreventive agents. FASEB 2002, 16:2-14
9. Zhou Y, Ran J, Tang C, Wu J, Honghua L, Xingwen L, Ning C, Qiao L: Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer. Cancer Biol Ther 2007, 6(2):e1-e7
10. Xiao H, Zhang Q, Lin Y, Reddy B, Yang C: Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 2008, 122:2115-2124
11. Wang H, Yang Y, Zhuang Y, Chen H, Wan Y, Huang Y: The effect of celecoxib on tissue factor expression in pancreatic cancer cells. Chin Med J 2007, 120(20):1753-1756
12. Konturek P, Konturek S, Brzozowski T: Gastric cancer and Helicobacter pylori infection. J Physiol Pharmacol 2006, 57(Suppl 3):51-65
13. Rosas C, Roa I, Sinning M, Fuenzalida M, Lemus D: Efecto de Celecoxib en una variante multirresistente del tumor TA3. Una descripción histológica. Int. J Morphol 2013, 31(2):392-398
14. Illanes J, Dabancens A, Acuña O, Fuenzalida M, Guerrero A, Lopez C, Lemus D: Effects of betamethasone, sulindac and quinacrine drugs on the inflammatory neoangiogenesis response induced by polyurethane sponge implanted in mouse. Biol Res 2002, 35:339-345
15. Chen P, Long Q: Effects of cyclooxygenase 2 inhibitors on biological traits of nasopharyngeal carcinoma cells. Acta Pharmacol Sin 2004, 25(7):943-949
16. Raut C, Nawrocki S, Lashinger L, Davis D, Khanbolooki S, Xiong H, Ellis L, Mcconkey D: Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther 2004, 3(12):1217-1224
17. Klenke F, Gebhard M, Ewerbeck V, Abdollahi A, Huber P, Sckell A: The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer 2006, 6:1-8
18. Harris RE, Alshafie GA, Abou-Issa H, Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000, 60:2101-2103
19. Jang TJ, Jung HG, Jung KH, O MK: Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours. Int J Exp Path 2002, 83:173-182
20. Dai Z, Ma X, Kang H, Gao J, Min W, Guan H, Diao Y, Lu W, Wang X: Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo. Cancer Cell Int 2012, 12(1):53
21. Yao L, Liu F, Hong L, Sun L, Liang S, Wu K, Fan D: The function and mechanism of COX-2 in angiogenesis of gastric cancer cells. J Exp Clin Cancer Res 2011, 30:13. doi:10.1186/1756-9966-30-13
22. Ghosh N, Chaki R, Mandal V, Mandal S: COX-2 as a target for cancer chemotherapy. Pharmacol Rep 2010, 62(2):233-244
23. Tarnawski A, Jones M: Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications. J Mol Med 2003, 81:627-636
24. Rüegg C: Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-angiogenic drugs. Haematologica reports 2006, 2(3):45-47
25. Kerbel R: Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049
26. Kim Y, Lee E, Kim Y, Kim S, Park J, Myoung H, Kim M: Anti-cancer effects of celecoxib in head and neck carcinoma. Mol Cell 2010, 29:185-194
27. Rodríguez DA, Tapia JC, Fernández JG, Torres VA, Muñoz N, Galleguillos D, Leyton L, Quest AFG: Caveolin-1-mediated suppression of cyclooxygenase-2 via a ß-catenin-Tcf/Lef-dependent transcriptional mechanism reduced PGE2 liberation and survivin expression. Mol Biol Cell 2009, 20:2297-2310
28. Vaish V, Sanyal S: Role of Sulindac and Celecoxib in the regulation of angiogenesis during the early neoplasm of colon: exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/ß-catenin signaling. Biomed Pharmacother 2012, 66(5):354-367
29. Brandao R, Veeck J, Van De Vijver K, Lindsey P, De Vries B, Van Elssen C, Blok M, Keymeulen K, Ayoubi T, Smeets H, Tjan-Heijnen V, Hupperets P: A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res 2013, 15(2):R29
30. Wu G, Zou S, Liu Z, Tang Z, Wang J: Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol 2003, 9(6):1302-1306
31. Jendrossek V: Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett 2013, 332:313-324
32. Wang D, Dubois R: Eicosanoids and cancer. Nat Rev Cancer 2010, 10:181-193
33. Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li W, Fan J, Gorlick R, Goker E, Bertino J: Molecular mechanisms of resistance to antifolates, a review. Acta Biochim Pol 1995, 42(4):457-464
34. Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS: Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1999, 26(12):2539-2543
35. El Bary NA, Hashem T, Metwally H, Ghany AA, El Mageed HA: A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma. Hematol Oncol Stem Cell Ther 2010, 3(1):13-18
36. Khan O, Blann A, Payne M, Middleton M, Protheroe A, Talbot D, Taylor M, Han C, Patil M, Harris A: Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br J Cancer 2011, 104:1822-1827
37. Venkatesan P, Puvvada N, Dash R, Kumar BNP, Sarkar D, Azab B, Pathak A, Kundu SC, Fisher P, Mandal M: The potential of Celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials 2011, 32:3794-3806
38. Kumar BNP, Rajput S, Dey KK, Parekh A, Das S, Mazumdar A, Mandal M: Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer 2013, 13:273
39. Li W, Tang Y, Wan L, Cai J, Zhang J: Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts. Oncol Lett 2013, 5:923-928
40. Molina MC, Ferreira V, Valck C, Aguilar L, Orellana J, Rojas A, Ramirez G, Billetta R, Schwaeble W, Lemus D, Ferreira A: An in vivo role for Trypanosoma cruzi calreticulin in antiangiogenesis. Mol Biochem Parasitol 2005, 140:133-140
41. Lopez N, Valck C, Ramirez G, Rodriguez M, Ribeiro C, Orellana J, Maldonado I, Albini A, Anacona D, Lemus D, Aguilar L, Schwaeble W, Ferreira A: Antiangiogenic and antitumor effects of Trypanosoma cruzi Calreticulin. Plos Negl Trop Dis 2010, 4(7):e730
42. Guerrero A, Zipper J, Dabancens A: Actividad antineoplásica ejercida por Quinacrina oral sobre tumores malignos trasplantables en ratón. Revista Chilena de Cancerología y Hematología 1992, 2:119-122
43. O'Reilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, Flynn E, Birkhead J, Olsen B, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285
44. Garrido O, Letelier R, Rosas C, Fuenzalida M, Ferreira A, Lemus D: Betamethasone inhibits tumor development, microvessel density and prolongs survival on mice with a multiresistant adenocarcinoma TA3. Biol Res 2010, 43:317-322